{"id":"https://openalex.org/W4388075693","doi":"https://doi.org/10.1136/jitc-2023-sitc2023.0737","title":"737 A phase 1/1b study of the tumor-activated IL-2 prodrug WTX-124 alone or in combination with pembrolizumab in patients with immunotherapy-sensitive locally advanced or metastatic solid tumors","display_name":"737 A phase 1/1b study of the tumor-activated IL-2 prodrug WTX-124 alone or in combination with pembrolizumab in patients with immunotherapy-sensitive locally advanced or metastatic solid tumors","publication_year":2023,"publication_date":"2023-10-31","ids":{"openalex":"https://openalex.org/W4388075693","doi":"https://doi.org/10.1136/jitc-2023-sitc2023.0737"},"language":"en","primary_location":{"id":"doi:10.1136/jitc-2023-sitc2023.0737","doi":"https://doi.org/10.1136/jitc-2023-sitc2023.0737","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2023-sitc2023.0737","pdf_url":"https://jitc.bmj.com/content/11/Suppl_1/A830.full.pdf","source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular and Young Investigator Award Abstracts","raw_type":"proceedings-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://jitc.bmj.com/content/11/Suppl_1/A830.full.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5082674870","display_name":"Justin C. Moser","orcid":"https://orcid.org/0000-0002-0643-6759","observed_orcids":["https://orcid.org/0000-0002-0643-6759"]},"institutions":[{"id":"https://openalex.org/I4210130412","display_name":"HonorHealth","ror":"https://ror.org/03szbwj17","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210130412"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Justin C Moser","raw_affiliation_strings":["HonorHealth Research Instittue, Scottsdale, AZ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"HonorHealth Research Instittue, Scottsdale, AZ, USA","institution_ids":["https://openalex.org/I4210130412"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079022151","display_name":"Mateusz Opyrchal","orcid":"https://orcid.org/0000-0003-2454-7441","observed_orcids":["https://orcid.org/0000-0003-2454-7441"]},"institutions":[{"id":"https://openalex.org/I1283055418","display_name":"Indiana University Health","ror":"https://ror.org/01aaptx40","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1283055418","https://openalex.org/I4388446366","https://openalex.org/I592451"]},{"id":"https://openalex.org/I4388446366","display_name":"Indiana University Indianapolis","ror":"https://ror.org/03eftgw80","country_code":"US","type":"education","lineage":["https://openalex.org/I4388446366","https://openalex.org/I592451"]},{"id":"https://openalex.org/I4390039234","display_name":"Indiana University Melvin and Bren Simon Comprehensive Cancer Center","ror":"https://ror.org/00g1d7b60","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4390039234","https://openalex.org/I592451"]},{"id":"https://openalex.org/I592451","display_name":"Indiana University","ror":"https://ror.org/01kg8sb98","country_code":"US","type":"education","lineage":["https://openalex.org/I592451"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mateusz Opyrchal","raw_affiliation_strings":["Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, IN, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, IN, USA","institution_ids":["https://openalex.org/I1283055418","https://openalex.org/I4388446366","https://openalex.org/I4390039234","https://openalex.org/I592451"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091619007","display_name":"Ildefonso Rodriguez-Rivera","orcid":"https://orcid.org/0000-0001-9211-1768","observed_orcids":["https://orcid.org/0000-0001-9211-1768"]},"institutions":[{"id":"https://openalex.org/I2800124591","display_name":"Texas Oncology","ror":"https://ror.org/02ketev28","country_code":"US","type":"facility","lineage":["https://openalex.org/I2800124591"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ildefonso Rodriguez Rivera","raw_affiliation_strings":["NEXT Oncology/Texas Oncology, San Antonio, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"NEXT Oncology/Texas Oncology, San Antonio, TX, USA","institution_ids":["https://openalex.org/I2800124591"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049071296","display_name":"Mehmet As\u0131m Bilen","orcid":"https://orcid.org/0000-0003-4003-1103","observed_orcids":["https://orcid.org/0000-0003-4003-1103"]},"institutions":[{"id":"https://openalex.org/I4390039307","display_name":"Winship Cancer Institute","ror":"https://ror.org/02gars961","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I132943300","https://openalex.org/I150468666","https://openalex.org/I4390039307"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mehmet A Bilen","raw_affiliation_strings":["Winship Cancer Institute of Emory University, Atlanta, GA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Winship Cancer Institute of Emory University, Atlanta, GA, USA","institution_ids":["https://openalex.org/I4390039307"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029588412","display_name":"Brendan D. Curti","orcid":"https://orcid.org/0000-0003-3948-2708","observed_orcids":["https://orcid.org/0000-0003-3948-2708"]},"institutions":[{"id":"https://openalex.org/I2801670537","display_name":"Providence Portland Medical Center","ror":"https://ror.org/015tmw922","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2801670537","https://openalex.org/I4210160466","https://openalex.org/I94396219"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Brendan Curti","raw_affiliation_strings":["Providence Cancer Institute, Franz Clinic, Portland, OR, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Providence Cancer Institute, Franz Clinic, Portland, OR, USA","institution_ids":["https://openalex.org/I2801670537"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049243227","display_name":"Igor J. Puzanov","orcid":"https://orcid.org/0000-0002-9803-3497","observed_orcids":["https://orcid.org/0000-0002-9803-3497"]},"institutions":[{"id":"https://openalex.org/I1292894508","display_name":"Roswell Park Comprehensive Cancer Center","ror":"https://ror.org/0499dwk57","country_code":"US","type":"facility","lineage":["https://openalex.org/I1292894508"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Igor Puzanov","raw_affiliation_strings":["Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA","institution_ids":["https://openalex.org/I1292894508"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112254438","display_name":"Kristin R. Morris","orcid":"https://orcid.org/0009-0006-9102-210X","observed_orcids":["https://orcid.org/0009-0006-9102-210X"]},"institutions":[{"id":"https://openalex.org/I4405263496","display_name":"Werewolf Therapeutics (United States)","ror":"https://ror.org/01wrd9933","country_code":"US","type":"company","lineage":["https://openalex.org/I4405263496"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kristin Morris","raw_affiliation_strings":["Werewolf Therapeutics, Watertown, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Werewolf Therapeutics, Watertown, MA, USA","institution_ids":["https://openalex.org/I4405263496"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061076537","display_name":"Christopher J. Nirschl","orcid":"https://orcid.org/0000-0002-7333-2757","observed_orcids":["https://orcid.org/0000-0002-7333-2757"]},"institutions":[{"id":"https://openalex.org/I4405263496","display_name":"Werewolf Therapeutics (United States)","ror":"https://ror.org/01wrd9933","country_code":"US","type":"company","lineage":["https://openalex.org/I4405263496"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Christopher J Nirschl","raw_affiliation_strings":["Werewolf Therapeutics, Watertown, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Werewolf Therapeutics, Watertown, MA, USA","institution_ids":["https://openalex.org/I4405263496"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022989853","display_name":"Saero Park","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405263496","display_name":"Werewolf Therapeutics (United States)","ror":"https://ror.org/01wrd9933","country_code":"US","type":"company","lineage":["https://openalex.org/I4405263496"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Saero Park","raw_affiliation_strings":["Werewolf Therapeutics, Watertown, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Werewolf Therapeutics, Watertown, MA, USA","institution_ids":["https://openalex.org/I4405263496"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011345666","display_name":"Marissa Bruno","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405263496","display_name":"Werewolf Therapeutics (United States)","ror":"https://ror.org/01wrd9933","country_code":"US","type":"company","lineage":["https://openalex.org/I4405263496"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Marissa Bruno","raw_affiliation_strings":["Werewolf Therapeutics, Watertown, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Werewolf Therapeutics, Watertown, MA, USA","institution_ids":["https://openalex.org/I4405263496"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046173491","display_name":"Paul Windt","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405263496","display_name":"Werewolf Therapeutics (United States)","ror":"https://ror.org/01wrd9933","country_code":"US","type":"company","lineage":["https://openalex.org/I4405263496"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Paul Windt","raw_affiliation_strings":["Werewolf Therapeutics, Watertown, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Werewolf Therapeutics, Watertown, MA, USA","institution_ids":["https://openalex.org/I4405263496"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005038640","display_name":"Kulandayan K. Subramanian","orcid":"https://orcid.org/0000-0002-7750-0025","observed_orcids":["https://orcid.org/0000-0002-7750-0025"]},"institutions":[{"id":"https://openalex.org/I4405263496","display_name":"Werewolf Therapeutics (United States)","ror":"https://ror.org/01wrd9933","country_code":"US","type":"company","lineage":["https://openalex.org/I4405263496"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kulandayan K Subramanian","raw_affiliation_strings":["Werewolf Therapeutics, Watertown, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Werewolf Therapeutics, Watertown, MA, USA","institution_ids":["https://openalex.org/I4405263496"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102747606","display_name":"Sameer S Chopra","orcid":"https://orcid.org/0000-0002-7969-0555","observed_orcids":["https://orcid.org/0000-0002-7969-0555"]},"institutions":[{"id":"https://openalex.org/I4405263496","display_name":"Werewolf Therapeutics (United States)","ror":"https://ror.org/01wrd9933","country_code":"US","type":"company","lineage":["https://openalex.org/I4405263496"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sameer S Chopra","raw_affiliation_strings":["Werewolf Therapeutics, Watertown, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Werewolf Therapeutics, Watertown, MA, USA","institution_ids":["https://openalex.org/I4405263496"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5031926846","display_name":"RANDI E. ISAACS","orcid":"https://orcid.org/0000-0003-0433-8976","observed_orcids":["https://orcid.org/0000-0003-0433-8976"]},"institutions":[{"id":"https://openalex.org/I4405263496","display_name":"Werewolf Therapeutics (United States)","ror":"https://ror.org/01wrd9933","country_code":"US","type":"company","lineage":["https://openalex.org/I4405263496"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Randi Isaacs","raw_affiliation_strings":["Werewolf Therapeutics, Watertown, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Werewolf Therapeutics, Watertown, MA, USA","institution_ids":["https://openalex.org/I4405263496"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":10,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":2490,"currency":"USD","value_usd":2490},"apc_paid":{"value":2490,"currency":"USD","value_usd":2490},"fwci":null,"has_fulltext":true,"cited_by_count":3,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":"A830","last_page":"A830"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.002099999925121665,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.9679999947547913},{"id":"https://openalex.org/keywords/anti-pd-1-combination-therapy","display_name":"anti-PD-1 combination therapy","score":0.8650000095367432},{"id":"https://openalex.org/keywords/cutaneous-melanoma","display_name":"cutaneous melanoma","score":0.9459999799728394},{"id":"https://openalex.org/keywords/renal-cell-carcinoma","display_name":"renal cell carcinoma","score":1.0},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.9670000076293945},{"id":"https://openalex.org/keywords/cd8-t-cell-expansion","display_name":"CD8+ T cell proliferation","score":0.6800000071525574},{"id":"https://openalex.org/keywords/first-in-human-safety","display_name":"first-in-human safety","score":0.5550000071525574},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.6899999976158142},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.4830000102519989}],"concepts":[{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.8342911601066589},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.5732746124267578},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5601128339767456},{"id":"https://openalex.org/C108215921","wikidata":"https://www.wikidata.org/wiki/Q603741","display_name":"Prodrug","level":2,"score":0.46169909834861755},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4421895146369934},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.40522530674934387},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3602668046951294},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.18041032552719116},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.12974971532821655}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1136/jitc-2023-sitc2023.0737","doi":"https://doi.org/10.1136/jitc-2023-sitc2023.0737","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2023-sitc2023.0737","pdf_url":"https://jitc.bmj.com/content/11/Suppl_1/A830.full.pdf","source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular and Young Investigator Award Abstracts","raw_type":"proceedings-article"},{"id":"pmh:oai:doaj.org/article:2c535f528fe849388924b327f27fc65e","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/2c535f528fe849388924b327f27fc65e","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1136/jitc-2023-sitc2023.0737","doi":"https://doi.org/10.1136/jitc-2023-sitc2023.0737","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2023-sitc2023.0737","pdf_url":"https://jitc.bmj.com/content/11/Suppl_1/A830.full.pdf","source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular and Young Investigator Award Abstracts","raw_type":"proceedings-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4388075693.pdf","grobid_xml":"https://content.openalex.org/works/W4388075693.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4365512249","https://openalex.org/W4399662709","https://openalex.org/W4220767421","https://openalex.org/W4282944927","https://openalex.org/W3213880233","https://openalex.org/W3177799967","https://openalex.org/W4388071286","https://openalex.org/W4224274268","https://openalex.org/W4404053122","https://openalex.org/W4415899153"],"abstract_inverted_index":{"Background":[0],"High-dose":[1],"IL-2":[2,37,61,80,314,394,418],"is":[3,21,64,99,358],"an":[4,36],"FDA-approved":[5],"immunotherapy":[6],"that":[7,419],"produces":[8],"durable":[9],"remissions":[10],"in":[11,49,73,117,163,193,230,269,291,325,372,398,484],"patients":[12,124,176,224,399,475],"with":[13,119,125,165,177,228,308,374,400],"melanoma":[14,182,253],"and":[15,83,90,107,201,205,214,238,255,276,287,328,335,346,423,467],"renal":[16],"cell":[17,248,337],"carcinoma":[18],"(RCC)":[19],"but":[20,46],"hampered":[22],"by":[23,54,439],"toxicities":[24],"arising":[25],"from":[26,58],"peripheral":[27],"immune":[28,216,336],"activation.":[29],"To":[30],"address":[31],"this":[32],"challenge,":[33],"we":[34],"engineered":[35],"INDUKINE":[38],"TM":[39],"molecule":[40,356],"(WTX-124)":[41],"to":[42,66,122,144,211,387,395,481],"be":[43,351],"administered":[44,112,152],"systemically":[45],"selectively":[47],"activated":[48,417],"the":[50,78,101,147,277,326,383,396,440,485],"tumor":[51,203,244,425],"microenvironment":[52],"(TME)":[53],"dysregulated":[55],"proteases.":[56],"Distinct":[57],"other":[59],"next-generation":[60],"molecules,":[62],"WTX-124":[63,111,151,188,229,303,357,386],"designed":[65],"release":[67],"a":[68,114,140,160,390,415],"fully":[69,391],"potent,":[70,392],"wild-type":[71,393],"cytokine":[72],"tumors.":[74],"In":[75,173],"preclinical":[76],"models,":[77],"released":[79],"causes":[81],"expansion":[82],"activation":[84],"of":[85,110,135,150,195,219,300,312,316,330,377,385,414],"tumor-infiltrating":[86,331],"CD8+":[87],"T":[88],"cells":[89],"generates":[91],"substantial":[92],"antitumor":[93,108,348,421],"activity.1":[94],"Methods":[95],"This":[96],"first-in-human":[97],"trial":[98],"investigating":[100],"safety,":[102,343],"pharmacokinetics":[103],"(PK),":[104],"pharmacodynamics,":[105],"immunogenicity,":[106],"activity":[109,349],"as":[113,159],"monotherapy":[115,161,189,232],"or":[116,162,179,183,190],"combination":[118,164,191],"pembrolizumab":[120,166],"(anti-PD-1)":[121],"adult":[123],"relapsed/refractory":[126],"solid":[127,401],"tumors":[128],"for":[129,323],"which":[130],"checkpoint":[131],"inhibitors":[132],"are":[133,208,320],"standard":[134],"care.":[136],"Dose":[137],"escalation":[138,234],"utilizes":[139],"mTPI-2":[141],"study":[142,435],"design":[143],"help":[145],"identify":[146],"recommended":[148],"dose":[149,174,233],"intravenously":[153],"(IV)":[154],"every":[155,170],"two":[156],"weeks":[157],"(Q2W)":[158],"400":[167],"mg":[168,363],"IV":[169,364],"six":[171],"weeks.":[172],"expansion,":[175],"advanced":[178],"metastatic":[180],"cutaneous":[181,252],"RCC":[184,256],"will":[185,350],"receive":[186],"either":[187],"therapy":[192],"one":[194],"four":[196],"arms":[197],"(n=20":[198],"patients/arm).":[199],"Pre-":[200],"on-treatment":[202],"biopsies":[204,319],"blood":[206],"samples":[207],"being":[209,321],"used":[210],"investigate":[212],"PK":[213,307,366],"multiple":[215],"parameters.Results":[217],"As":[218],"June":[220],"22,":[221],"2023,":[222],"11":[223],"have":[225,260],"been":[226,261],"treated":[227],"three":[231,292],"cohorts":[235],"(1,":[236],"3,":[237],"6":[239],"mg).":[240],"The":[241,281,353,380,434],"most":[242,282],"common":[243,283],"types":[245],"include":[246],"non-small":[247],"lung":[249],"cancer":[250],"(n=4),":[251],"(n=3),":[254],"(n=2).":[257],"No":[258,294],"DLTs":[259],"reported.":[262],"Of":[263],"19":[264],"treatment-related":[265],"AEs":[266],"(TRAEs)":[267],"occurring":[268,290],"5":[270],"patients,":[271],"26%":[272],"were":[273,285],"Grade":[274,279],"2":[275],"remainder":[278],"1.":[280],"TRAEs":[284],"fatigue":[286],"arthralgias,":[288],"each":[289,446],"patients.":[293],"patient":[295],"developed":[296],"capillary":[297],"leak":[298],"syndrome":[299],"any":[301],"grade.":[302],"exhibits":[304],"approximately":[305],"dose-proportional":[306],"very":[309],"low":[310,375],"levels":[311,376],"active":[313,378],"(<1%":[315],"prodrug).":[317],"Tumor":[318],"analyzed":[322],"changes":[324],"frequency":[327],"functionality":[329],"lymphocytes,":[332],"PD-L1":[333],"expression,":[334],"gene":[338],"expression.":[339],"Updated":[340],"data":[341,367,381],"on":[342],"PK,":[344],"biomarkers,":[345],"preliminary":[347],"presented.Conclusions":[352],"novel":[354],"INDUKINE\u2122":[355],"well-tolerated":[359],"at":[360,445],"doses":[361],"\u22646":[362],"Q2W.":[365],"show":[368],"sustained":[369],"prodrug":[370],"exposure":[371],"plasma":[373],"IL-2.":[379],"demonstrate":[382],"potential":[384],"safely":[388],"deliver":[389],"TME":[397],"tumors.Trial":[402],"Registration":[403],"NCT05479812Reference":[404],"Nirschl":[405],"CJ,":[406],"Brodkin":[407],"HR,":[408],"Hicklin":[409],"DJ,":[410],"et":[411],"al.":[412],"Discovery":[413],"conditionally":[416],"promotes":[420],"immunity":[422],"induces":[424],"regression.":[426],"Cancer":[427,469],"Immunol":[428],"Res.":[429],"2022":[430],"May":[431],"3;10(5):581\u2013596.Ethics":[432],"Approval":[433],"protocol":[436],"was":[437],"approved":[438],"institutional":[441],"review":[442],"(ethics)":[443],"board":[444],"participating":[447],"clinical":[448],"site.":[449],"These":[450],"include:":[451],"HonorHealth":[452],"(WIRB,":[453,456],"#IRB-22\u20130043);":[454],"Emory":[455],"#STUDY00004612);":[457],"NEXT":[458],"Oncology":[459],"(Salus":[460],"IRB,":[461,472],"#NXSAT21.151);":[462],"Indiana":[463],"University":[464],"(IRB,":[465],"#15531);":[466],"Providence":[468],"Institute":[470],"(PSJH":[471],"#STUDY2022000507).":[473],"All":[474],"provided":[476],"written":[477],"informed":[478],"consent":[479],"prior":[480],"taking":[482],"part":[483],"study.":[486]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1}],"updated_date":"2026-11-02T09:45:03.842371","created_date":"2023-11-01T00:00:00"}